Kyverna Therapeutics Raises $85M in Series B Financing
Summary
The therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress or eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. The company intends to use the funds to advance KYV-101, an autologous version of a novel clinical-stage anti-CD19 chimeric antigen receptor T-cell (CAR T) construct with properties suited for use in B cell-driven autoimmune diseases such as lupus nephritis, systemic sclerosis, and inflammatory myopathies. Kyverna has obtained exclusive, worldwide licenses from the National Institutes of Health (NIH) to use this novel CD19 construct in both autologous and allogeneic CAR T-cell therapies. Consistent with a recently announced licensing and collaboration agreement between Kyverna and Intellia Therapeutics, the financing proceeds will also be used to support the development of KYV-201, an investigational candidate for the treatment of select B cell-driven autoimmune diseases combining the company’s novel CD19 CAR T construct with Intellia’s proprietary ex vivo CRISPR/Cas9-based allogeneic platform. Kyverna has established a strategic collaboration and license agreement with Gilead to develop engineered T-cell therapies for the treatment of autoimmune diseases based on Kyverna’s synReg T-cell platform and synNotch technology from Kite, a Gilead Company.
Funding
Review available funding amount, funding date, investors, and linked company information related to Kyverna Therapeutics Raises $85M in Series B Financing in the interactive ISVWorld profile.